Lisata Therapeutics announces research license with Catalent

CAR-T Digest - August 2020

15 Apr 2025: Lisata Therapeutics announces research license with Catalent

Lisata Therapeutics has entered a research license agreement with Catalent to assess its peptide candidate, Certe petide, in combination with Catalent’s SMARTag ADC platform in preclinical studies targeting advanced solid tumors
The collaboration aims to combine Certepetide’s tumor-penetrating capabilities with ADCs’ targeted delivery to enhance precision oncology and reduce systemic toxicity
Catalent will cover all research and development expenses, while Lisata will offer consulting support and receive an upfront payment, with potential for additional payments based on preclinical results
Certepetide is expected to improve the effectiveness of ADCs by enabling deeper tumor penetration and reducing the immunosuppressive effects of the tumor microenvironment
Both companies expressed optimism about the potential of this partnership to create more effective and innovative cancer therapies